Phenotypes associated with this allele

• Allele Symbol: Tg(Igh-6-Cd80)1Gjf
• Allele Name: transgene insertion 1, Gordon J Freeman
• Allele ID: MGI:3656398
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
tg1	Tg(Igh-6-Cd80)1Gjf/0	B6.Cg-Tg(Igh-6-Cd80)1Gjf	MGI:3662664
tg2	Tg(Igh-6-Cd80)1Gjf/0	involves: BALB/c * C57BL/6 * CBA	MGI:3662666
tg3	Tg(Igh-6-Cd80)1Gjf/0	involves: FVB	MGI:3662632
tg4	Tg(Igh-6-Cd80)1Gjf/0	NOD.FVB-Tg(Igh-6-Cd80)1Gjf/JbsJ	MGI:3823088

Genotype
MGI:3662664

tg1

• Allelic Composition: Tg(Igh-6-Cd80)1Gjf/0
• Genetic Background: B6.Cg-Tg(Igh-6-Cd80)1Gjf

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

hematopoietic system phenotype ( J:112266 )

N • there is no significant difference in lymphoid organ cellularity compare to Cd86 transgenic mice

abnormal T cell number ( J:112266 )

• CD4/CD8 ratios in the thymus and spleen are significantly lower than those of control littermates

immune system

abnormal T cell number ( J:112266 )

• CD4/CD8 ratios in the thymus and spleen are significantly lower than those of control littermates

Genotype
MGI:3662666

tg2

• Allelic Composition: Tg(Igh-6-Cd80)1Gjf/0
• Genetic Background: involves: BALB/c * C57BL/6 * CBA

hematopoietic system

hematopoietic system phenotype ( J:112266 )

N • there is no significant difference in lymphoid organ cellularity compare to Cd86 transgenic mice

Genotype
MGI:3662632

tg3

• Allelic Composition: Tg(Igh-6-Cd80)1Gjf/0
• Genetic Background: involves: FVB

immune system

decreased B cell number ( J:44271 )

• a defect in B cell maturation similar to that in Tg(Igh-6-Cd80)1Gjf mice is observed

• 3 week old transgenics have fewer B cells than wild-type mice; percentage of B cells in the spleens of young wild-type is 54% vs 25% in transgenics

• adult mice have comparable numbers of B cells in the spleens to wild-type

abnormal CD4-positive, alpha-beta T cell physiology ( J:44271 )

• transgene expressing T cells can be activated by anti-CD3 alone, whereas wild-type T cells require presence of costimulatory signals for activation

abnormal T cell activation ( J:44271 )

• T cells stimulated with wild-type B cells show poor activation in contrast to cells stimulated with B cells expressing the transgene

abnormal humoral immune response ( J:112474 )

• in response to TNP-KLH, T cell responses are normal but B cell antibody responses are reduced

• when mice are treated with anti-Cd80, capacity to produce antibodies in response to hapten-protein conjugates is restored

decreased immunoglobulin level ( J:112474 )

• all Ig isotypes are reduced in transgenic mice in response to TNP-KLH; the same defect is seen with another hapten conjugate TNP-ovalbumin

hematopoietic system

decreased B cell number ( J:44271 )

• a defect in B cell maturation similar to that in Tg(Igh-6-Cd80)1Gjf mice is observed

• 3 week old transgenics have fewer B cells than wild-type mice; percentage of B cells in the spleens of young wild-type is 54% vs 25% in transgenics

• adult mice have comparable numbers of B cells in the spleens to wild-type

decreased immunoglobulin level ( J:112474 )

• all Ig isotypes are reduced in transgenic mice in response to TNP-KLH; the same defect is seen with another hapten conjugate TNP-ovalbumin

abnormal CD4-positive, alpha-beta T cell physiology ( J:44271 )

• transgene expressing T cells can be activated by anti-CD3 alone, whereas wild-type T cells require presence of costimulatory signals for activation

abnormal T cell activation ( J:44271 )

• T cells stimulated with wild-type B cells show poor activation in contrast to cells stimulated with B cells expressing the transgene

Genotype
MGI:3823088

tg4

• Allelic Composition: Tg(Igh-6-Cd80)1Gjf/0
• Genetic Background: NOD.FVB-Tg(Igh-6-Cd80)1Gjf/JbsJ

immune system

insulitis ( J:131077 )

• mononuclear infiltration is present, but reduced, in pancreatic islets as compared to control

decreased B cell number ( J:131077 )

• Background Sensitivity: reduction in percentage of circulating B cells beginning at 2 weeks of age

• treatment with anti-Cd8 mAb beginning at 3 weeks of age results in an increase in the percentage of B cells to almost control levels

• B cells represent 2-3% of cells in blood in contrast to 20-30% found in NOD controls

• 2 - 2.5 fold reduction of splenic B cells as compared to NOD controls

• immature/mature (B220+, IgM+) B cells reduced more than 10 fold in bone marrow

decreased immature B cell number ( J:131077 )

• immature/mature (B220+, IgM+) B cells are reduced more than 10 fold in bone marrow

decreased mature B cell number ( J:131077 )

decreased B-2 B cell number ( J:131077 )

• percentage of B-2 B cells is decreased greater than 5 fold in the peritoneal cavity, however, numbers of B-1 B cells are not significantly changed

decreased follicular B cell number ( J:131077 )

• severe depletion of mature (CD2 1ow IgM low) follicular B cells in spleen, however, marginal zone B cells are mostly unaffected

abnormal B cell activation ( J:131077 )

• splenic transgenic B cells proliferate in cell transfer experiments

decreased immunoglobulin level ( J:131077 )

• circulating IgM, IgG2b, IgG3 and IgG1 levels reduced

• treatment with anti-Cd8 mAb beginning at 3 weeks of age results in an increase in circulating immunoglobulin levels

decreased IgG1 level ( J:131077 )

decreased IgG2b level ( J:131077 )

decreased IgG3 level ( J:131077 )

decreased IgM level ( J:131077 )

abnormal CD8-positive, alpha-beta T cell physiology ( J:131077 )

• CD8+ T cell depletion leads to restoration of B cell numbers

abnormal level of surface class II molecules ( J:131077 )

• class II expression is increased by 2 fold in splenic B cells

decreased susceptibility to autoimmune diabetes ( J:131077 )

• transgenic mice do not develop diabetes

hematopoietic system

abnormal bone marrow cell number ( J:131077 )

• decrease in number of B cells in bone marrow

• pre/pro (B220+, IgM-) B cells are reduced less than 2 fold

• immature/mature (B220+, IgM+) B cells are reduced more than 10 fold

decreased B cell number ( J:131077 )

• Background Sensitivity: reduction in percentage of circulating B cells beginning at 2 weeks of age

• treatment with anti-Cd8 mAb beginning at 3 weeks of age results in an increase in the percentage of B cells to almost control levels

• B cells represent 2-3% of cells in blood in contrast to 20-30% found in NOD controls

• 2 - 2.5 fold reduction of splenic B cells as compared to NOD controls

• immature/mature (B220+, IgM+) B cells reduced more than 10 fold in bone marrow

decreased immature B cell number ( J:131077 )

• immature/mature (B220+, IgM+) B cells are reduced more than 10 fold in bone marrow

decreased mature B cell number ( J:131077 )

decreased B-2 B cell number ( J:131077 )

• percentage of B-2 B cells is decreased greater than 5 fold in the peritoneal cavity, however, numbers of B-1 B cells are not significantly changed

decreased follicular B cell number ( J:131077 )

• severe depletion of mature (CD2 1ow IgM low) follicular B cells in spleen, however, marginal zone B cells are mostly unaffected

abnormal B cell activation ( J:131077 )

• splenic transgenic B cells proliferate in cell transfer experiments

decreased immunoglobulin level ( J:131077 )

• circulating IgM, IgG2b, IgG3 and IgG1 levels reduced

• treatment with anti-Cd8 mAb beginning at 3 weeks of age results in an increase in circulating immunoglobulin levels

decreased IgG1 level ( J:131077 )

decreased IgG2b level ( J:131077 )

decreased IgG3 level ( J:131077 )

decreased IgM level ( J:131077 )

abnormal CD8-positive, alpha-beta T cell physiology ( J:131077 )

• CD8+ T cell depletion leads to restoration of B cell numbers

endocrine/exocrine glands

insulitis ( J:131077 )

• mononuclear infiltration is present, but reduced, in pancreatic islets as compared to control